To improve the efficacy of Delta-24-RGD, a new generation of adenovirus, named Delta-24-RGDOX, was developed to express the immune costimulatory OX40 ligand (OX40L), which enhances tumor-specific T cell activation as well as the antigen-presenting capabilities of tumor cells [110]. This evidence concerns the gene TNFSF4 and neoplasm.